Loading...
Market
What percentage of Zydus Lifesciences' revenue will ZyVac TCV contribute in FY 2025?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Zydus Lifesciences' financial reports
Story
Zydus Lifesciences' ZyVac TCV Typhoid Vaccine Gets WHO Approval
Oct 23, 2024, 05:24 AM
Zydus Lifesciences Ltd announced on Wednesday that its Typhoid Vi conjugate vaccine, ZyVac TCV, has received in-principle approval from the World Health Organization (WHO). This prequalification marks a significant step for the company in addressing typhoid, a serious infectious disease. The WHO prequalification is essential for global health initiatives as it ensures the vaccine meets international standards for quality, safety, and efficacy. This approval will potentially enhance Zydus Lifesciences' market reach and contribute to global efforts in combating typhoid.
View original story
Similar markets
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
<$300 million • 25%
$300-500 million • 25%
$500-700 million • 25%
>$700 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
